Human cytomegalovirus gb polypeptide
US-2022088184-A1 · Mar 24, 2022 · US
Human cytomegalovirus gB polypeptide
US11629172B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11629172-B2 |
| Application number | US-201916721229-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 19, 2019 |
| Priority date | Dec 21, 2018 |
| Publication date | Apr 18, 2023 |
| Grant date | Apr 18, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2-45 and 47-106. 2. The polypeptide according to claim 1 , wherein the sequence comprises SEQ ID NO: 56. 3. The polypeptide according to claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 57. 4. The polypeptide according to claim 1 , wherein the sequence comprises SEQ ID NO: 58. 5. The polypeptide according to claim 1 , wherein the sequence comprises SEQ ID NO: 75. 6. A polynucleotide encoding a polypeptide comprising an amino acid sequence set forth in any one of SEQ ID Nos: 2-45 and 47-106. 7. A composition comprising a polypeptide of claim 1 and a diluent. 8. The composition according to claim 7 , wherein the composition does not comprise a polypeptide having the amino acid sequence set forth in any one of SEQ ID NO: 59, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 71, SEQ ID NO: 52, SEQ ID NO: 96, and SEQ ID NO: 50. 9. The composition according to claim 7 , further comprising a polypeptide comprising any one amino acid sequence selected from SEQ ID NOS: 211-224. 10. A composition comprising a polynucleotide encoding a polypeptide comprising the sequence selected from any one of SEQ ID Nos: 2-45 and 47-106; and a diluent. 11. The composition according to claim 10 , further comprising a polynucleotide comprising a sequence selected from any one of SEQ ID NOS: 141-210. 12. The composition according to claim 10 , further comprising a polynucleotide comprising a sequence selected from any one of SEQ ID NOS: 224-254. 13. A method of eliciting an immune response in a mammal, comprising administering an effective amount of a composition comprising a polypeptide comprising the sequence set forth in any one of SEQ ID Nos: 2-45 and 47-106; and a diluent. 14. A method of eliciting an immune response in a mammal, comprising administering an effective amount of a composition comprising a polynucleotide encoding a polypeptide comprising the sequence set forth in any one of SEQ ID Nos: 2-45 and 47-106; and a diluent.
Assignees
Inventors
Classifications
Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
- C07K14/005Primary
from viruses · CPC title
Viral antigens · CPC title
DNA (RNA) vaccination · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11629172B2 cover?
- The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and u…
- Who is the assignee on this patent?
- Pfizer
- What technology area does this patent fall under?
- Primary CPC classification C07K14/005. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).